bioMérieux stock breaks through its 75.80 € resistance level and rebounds by more than 3%
bioMérieux stands out as one of the rare equities resisting the general decline in European markets this Thursday, pushing its price beyond a technical threshold it had already tested in early September. The move comes on the same day as the commercial launch of Spinchip, a rapid testing platform intended for emergency services, and a confirmation of an analyst's opinion.
A breakthrough of the 75.80 € resistance placing the security among the strongest gains of the SBF 120
bioMérieux gains 3.27% to 77.35 € during the session, ranking among the strongest increases of the SBF 120 while the index declines 0.26%. The security has broken upward through its 75.80 € resistance and is maintaining it, extending a movement already initiated in early September: the 75.80 € threshold had then been briefly touched before the security returned below this level. This time, the maintenance above appears more solid, especially as the price now exceeds its 20-day (73.24 €) and 50-day (72.78 €) moving averages with respective gaps of 5.61% and 6.28%.
The 200-day MA, at 84.20 €, remains nevertheless above the current price. The RSI at 59 reflects genuine buying momentum, without reaching the overbought zone. Over the week, the security advances 6.76%, and 16.14% over three months, which contrasts with a decline of 32.27% over one year.
The launch of Spinchip and a maintained analyst opinion at buy with 100 € target gives substance to the rebound
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The fundamental context of the day provides dual support for the movement. bioMérieux presented this Thursday its Spinchip platform, a troponin test achievable in ten minutes in emergency departments, one year after the acquisition of Norwegian company Spinchip Diagnostics. This launch is part of the group's GO-28 strategic plan, which aims for organic revenue growth of between 3% and 5% for the 2026 fiscal year, according to the outlook communicated when publishing first-half results on August 4, 2026. In parallel, CIC Market Solutions confirmed today its buy opinion on the security with a price target maintained at 100 €, representing an upside potential of nearly 29% compared to the current price. The analysts' view thus aligns with today's technical momentum. The next level to watch remains the 101 € resistance, a threshold the group has not revisited in several months.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1 965 millions d'euros
Quarterly revenue: 1 965 millions d'euros
Revenue growth: -3,9 %
EBITDA: 440,3 millions d'euros
EBITDA margin: 22,4 %
Net income: 226,1 millions d'euros
Free cash flow: 299 millions d'euros
-235,9 millions d'euros
Guidance from the release
confirme ses perspectives pour 2026 : croissance organique du chiffre d'affaires comprise entre +3% et +5%, CEBIT croissance comprise entre 0% et +10%
Risks mentioned
Épidémiologie respiratoire plus faible : recul organique de 17 % des panels respiratoires BIOFIRE®
Effet de change défavorable de 35 M€ sur le ROCC du premier semestre 2026
Environnement géopolitique et macroéconomique dégradé depuis 2024
Opportunities identified
Croissance organique de 6 % des quatre moteurs de croissance du plan GO•28
Dépôt auprès de la FDA du panel SPOTFIRE® Vaginitis
Obtention du marquage CE du premier test SPINCHIP®
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
